Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3361237 - SC
LY3361237 · 2 trials · 2 indications
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3361237 | EXPERIMENTAL | LY3361237 administered subcutaneously (SC). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3361237 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have chronic plaque psoriasis for at least 6 months * Be willing and able to undergo skin biopsies * Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²) * Female participants must agree to use birth control during the study Exclusion Criteri...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
LY3361237 is an investigational small molecule being developed by Eli Lilly and Company for immunology indications. It has been studied in Phase 1 clinical trials in participants with systemic lupus erythematosus and psoriasis. It is not yet approved for any use and remains in early clinical development.
LY3361237 has been studied in clinical trials for systemic lupus erythematosus and psoriasis, two immune-mediated conditions. Both programs were Phase 1 studies designed to evaluate the drug in adults with these diseases. No approved indication currently exists for LY3361237.
Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY, is the developer of LY3361237. The company sponsored the Phase 1 clinical trials of the drug in systemic lupus erythematosus and psoriasis.
LY3361237 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in systemic lupus erythematosus and one in psoriasis. The drug is investigational and has not been approved by the FDA or any other regulatory agency for commercial use.
LY3361237 has been evaluated in two completed Phase 1 trials. NCT03933943 studied the drug in 28 participants with systemic lupus erythematosus in the United States. NCT04975295 studied it in 21 participants with psoriasis across Bulgaria, Hungary, Poland, and Slovakia. Both trials enrolled adults aged 18 and older.
Yes, LY3361237 - SC is an alternative name used for LY3361237. Both names refer to the same investigational small molecule developed by Eli Lilly and Company for systemic lupus erythematosus and psoriasis. Searches using either name point to the same drug asset.